Jeff McMullen Elected 2012 ACRO Chairman

Contact: John Lewis


[email protected]

PharmaNet/i3 CEO Jeff McMullen Elected
2012 ACRO Chairman

December 1, 2011 – WASHINGTON, D.C. – The Association of Clinical Research Organizations (ACRO) today announced its Board of Directors has elected Jeffrey P. McMullen as its 2012 Chairman. Mr. McMullen is President and Chief Executive Officer of PharmaNet/i3, the clinical segment of inVentiv Health, and previously served as ACRO Chairman in 2007.

“ACRO members, to a large extent, comprise the global drug development infrastructure and I am pleased to lead the organization at a time when our expertise is being recognized by our biopharmaceutical clients, as well as regulators worldwide,” said Mr. McMullen. “I look forward to advancing ACRO’s advocacy, research and communications agendas in 2012.”

Mr. McMullen’s experience in the drug development industry spans more than 35 years. He spent 13 years with major contract research organizations as Vice President of Business Development and Director of Clinical Research, and 9 years at Sterling Drug (now Sanofi) in the clinical, regulatory, and drug metabolism areas. Mr. McMullen, co-founder of PharmaNet/i3, also has extensive international experience including Europe, Japan, South America, and Asia.

“Jeff is the first ACRO board member to twice be elected Chairman, which is a strong testament to his vision and leadership, as well as the high regard in which he is held by his peers,” said Doug Peddicord, PhD, Executive Director of ACRO.

Josef H. von Rickenbach, a founding member of ACRO, and Chairman and CEO of PAREXEL International (NASDAQ: PRXL) will serve as Chair-elect in 2012.

About ACRO
The Association of Clinical Research Organizations (ACRO) represents companies that provide a variety of specialized services that support the development of new pharmaceuticals, biologics and medical devices. The association provides an active voice for the CRO industry globally. Through its member companies, ACRO helps improve the quality, efficiency and safety of biomedical research. ACRO member companies employ approximately 72,000 professionals worldwide and annually conduct more than 11,000 clinical trials involving nearly two million participants in 115 countries. For more information, please visit Twitter @acrohealth.

Download as PDF

Scroll to Top